None listed
Conditions
Brief summary
Regional citrate anticoagulation (RCA) for continuous renal replacement therapy is associated with longer filter-life and less bleeding events. Complexity of the regimen is the major hurdle preventing its wide spread applications. Our intensive Care Unit has been using a concentrated citrate containing solution for continuous venovenous hemofiltration (CVVH) for more than ten years already. We have been using another proprietary product of diluted citrate solution (Prismocitrate 10/2, Gambro) for predilutional continuous veno-venous hemofiltration (CVVH) since 2009. This is a retrospective case review for patients received this diluted citrate solution (Prismocitrate 10/2, Gambro).
Interventions
The Prismaflex system (Gambro-Hospal) was used for predilution continuous venovenous hemofiltration (CVVH). Prismocitrate 10/2, running at 2500ml/h, was the main predilution replacement. 8.4% sodium bicarbonate solution was infused at 50ml/h in the first 2 hours, and then at 30ml/h, via the ‘Heparin port’ of the circuit (pre-filter). 10% calcium gluconate was infused via a separate central venous catheter to achieve an ionized calcium (iCa) level of 1-1.2mmol/L. The fluid withdrawal rate was
The Prismaflex system (Gambro-Hospal) was used for predilution continuous venovenous hemofiltration (CVVH). Prismocitrate 10/2, running at 2500ml/h, was the main predilution replacement. 8.4% sodium bicarbonate solution was infused at 50ml/h in the first 2 hours, and then at 30ml/h, via the ‘Heparin port’ of the circuit (pre-filter). 10% calcium gluconate was infused via a separate central venous catheter to achieve an ionized calcium (iCa) level of 1-1.2mmol/L. The fluid withdrawal rate was adjusted to achieve the desired fluid balance. The circuit was run for 72-hours, unless there was filter clotting, requirement of transportation outside ICU for intervention/ imaging, or the patient did not require further CRRT
Sponsors
Department of intensive care, Pamela Youde Nethersole Eastern Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
All patients who received citrate containing solution (Prismocitrate 10/2) for predilution continuous venovenous hemofiltration during study period
Exclusion criteria
Cases with insufficient data for analysis
Outcome results
None listed